BioNeutra Global Corporation
BGA.V
TSX
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -25.00% | -16.59% | -28.62% | -43.84% | -16.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.00% | -16.59% | -28.62% | -43.84% | -16.81% |
| Cost of Revenue | -34.91% | -4.88% | -11.62% | -31.36% | -21.81% |
| Gross Profit | 4.23% | -55.46% | -68.85% | -459.72% | 2.54% |
| SG&A Expenses | -10.24% | 7.29% | 19.02% | -32.34% | 27.29% |
| Depreciation & Amortization | 39.60% | 57.09% | 40.89% | 127.81% | -85.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.37% | 3.11% | -3.65% | -25.35% | -14.54% |
| Operating Income | 27.95% | -276.21% | -346.30% | -28.93% | -5.40% |
| Income Before Tax | -5.54% | -97.52% | -847.21% | -72.71% | -55.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.54% | -97.52% | -847.21% | -72.71% | -55.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.54% | -97.52% | -847.21% | -72.71% | -55.90% |
| EBIT | 27.95% | -276.21% | -346.30% | -28.93% | -5.40% |
| EBITDA | 64.55% | -84,914.29% | -185.20% | -103.99% | -21.87% |
| EPS Basic | -4.93% | -95.05% | -830.00% | -72.97% | -56.15% |
| Normalized Basic EPS | 55.12% | -95.24% | -641.18% | 26.83% | -56.79% |
| EPS Diluted | 2.61% | -120.79% | -840.00% | -72.97% | -44.65% |
| Normalized Diluted EPS | 55.12% | -95.24% | -641.18% | 26.83% | -56.79% |
| Average Basic Shares Outstanding | 0.54% | 0.54% | 0.54% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.54% | 0.54% | 0.54% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
